Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MET D1010H

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MET amplification + EGFR mutation (8)

EGFR mutation + MET amplification (5)

ALK rearrangement + MET amplification (3)

EGFR mutation + MET overexpression (3)

MET amplification + MET Exon 14 mutation (3)

MET elevation (3)

MET overexpression + EGFR mutation (3)

BRAF mutation + MET amplification (2)

CD74-ROS1 fusion + MET D1228N + MET amplification (2)

EGFR exon 19 deletion + MET amplification (2)

EGFR exon 19 deletion + MET Amplification + MET D1228V (2)

MET amplification + MET overexpression (2)

PD-L1 overexpression + MET exon 14 mutation (2)

STRN-ALK fusion + MET amplification (2)

ALK rearrangement + MET amplification (1)

CAPZA2-MET fusion + MET amplification (1)

EGFR C797S + MET amplification (1)

EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)

EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)

EGFR L858R + MET amplification (1)

EGFR L858R + MET overexpression (1)

EGFR L858R + MET positive (1)

EGFR T263P + EGFR L858R + MET amplification (1)

EGFR T790M + MET amplification (1)

EGFR T790M + MET positive (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + MET positive (1)

EGFR exon 19 deletion + MET amplification (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)

EGFR mutation + MET amplification + EGFR amplification (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + MET overexpression + MET amplification (1)

EGFR mutation + MET-CEP7 fusion (1)

EGFR wild-type + MET amplification (1)

EGFR wild-type + MET overexpression (1)

IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIF5B-RET fusion + MET amplification (1)

MET amplification + KLC1-ALK fusion (1)

MET amplification + MET exon 14 mutation + EGFR exon 20 insertion (1)

MET amplification + PIK3CA mutation (1)

MET amplification + RB1 wild-type (1)

MET amplification + RET fusion (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MET exon 14 mutation + ALK wild-type (1)

MET exon 14 mutation + EGFR wild-type (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MET exon 14 mutation + MET overexpression (1)

MET mutation + TMB-H (1)

MET negative + EGFR mutation (1)

MET overexpression + EGFR wild-type (1)

MET positive + EGFR mutation (1)

PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)

ROS1 positive + MET amplification (1)

TFE3 rearrangement + MET expression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

MET amplification + EGFR mutation (8)

EGFR mutation + MET amplification (5)

ALK rearrangement + MET amplification (3)

EGFR mutation + MET overexpression (3)

MET amplification + MET Exon 14 mutation (3)

MET elevation (3)

MET overexpression + EGFR mutation (3)

BRAF mutation + MET amplification (2)

CD74-ROS1 fusion + MET D1228N + MET amplification (2)

EGFR exon 19 deletion + MET amplification (2)

EGFR exon 19 deletion + MET Amplification + MET D1228V (2)

MET amplification + MET overexpression (2)

PD-L1 overexpression + MET exon 14 mutation (2)

STRN-ALK fusion + MET amplification (2)

ALK rearrangement + MET amplification (1)

CAPZA2-MET fusion + MET amplification (1)

EGFR C797S + MET amplification (1)

EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)

EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)

EGFR L858R + MET amplification (1)

EGFR L858R + MET overexpression (1)

EGFR L858R + MET positive (1)

EGFR T263P + EGFR L858R + MET amplification (1)

EGFR T790M + MET amplification (1)

EGFR T790M + MET positive (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + MET positive (1)

EGFR exon 19 deletion + MET amplification (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)

EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)

EGFR mutation + MET amplification + EGFR amplification (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + MET overexpression + MET amplification (1)

EGFR mutation + MET-CEP7 fusion (1)

EGFR wild-type + MET amplification (1)

EGFR wild-type + MET overexpression (1)

IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIF5B-RET fusion + MET amplification (1)

MET amplification + KLC1-ALK fusion (1)

MET amplification + MET exon 14 mutation + EGFR exon 20 insertion (1)

MET amplification + PIK3CA mutation (1)

MET amplification + RB1 wild-type (1)

MET amplification + RET fusion (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MET exon 14 mutation + ALK wild-type (1)

MET exon 14 mutation + EGFR wild-type (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MET exon 14 mutation + MET overexpression (1)

MET mutation + TMB-H (1)

MET negative + EGFR mutation (1)

MET overexpression + EGFR wild-type (1)

MET positive + EGFR mutation (1)

PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)

ROS1 positive + MET amplification (1)

TFE3 rearrangement + MET expression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

›

5ms

Comprehensive genomic profiling of tumour spatial heterogeneity for clinically-actionable genomic alterations (ECP 2024)

CDx-associated SV, CNA, and RE were concordant across intra-tumoural space, consistent with early emergence (a.k.a. truncal mutation) and stability during tumorigenesis. Overall, these results have important implications for diagnostic testing, including patient biopsy/surgical sampling and laboratory microdissection practices, which we find to be sound for the detection of therapy-related AGA in this study.

5 months ago

Clinical

|

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog)

|

BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • EGFR L858R • PTEN mutation • ALK fusion • RAS wild-type • EGFR mutation + PTEN mutation • MET D1010H

|

FoundationOne® CDx

over2years

Characterization of MET exon 14 skipping in pancancer. (ASCO 2022)

Here we reported diverse METex14 alterations in a Chinese pan-cancer cohort that contribute to oncogenic transformation. METex14 mutations of pan-cancer mainly occurred in SD site. TP53 was its main co-mutant gene among pan-cancers, and MET amplification was also observed.

over 2 years ago

Pan tumor

|

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)

|

TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET exon 14 mutation • EML4-ALK fusion • ALK fusion • CDK4 amplification • MET fusion • MET D1010H